NCT06298708View on ClinicalTrials.gov

Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 27, 2024

Primary Completion Date

December 9, 2024

Study Completion Date

December 9, 2024

Conditions
HAVHepatitis AHep AVaccine-Preventable Diseases
Interventions
BIOLOGICAL

Mevac-A vaccine

"Mevac-A: A freeze-dried live-attenuated hepatitis A vaccine.~Dose and administration: a freeze-dried live-attenuated vaccine, subcutaneous injection of 0.5 ml will be administered for 1 time."

BIOLOGICAL

Havrix 720 Junior

"Havrix 720 Junior: An inactivated hepatitis A vaccine, 720 ELISA units per 0.5 ml of formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain).~Dose and administration: a pre-filled syringe, intramuscular injection of 0.5 ml will be administered for 2 times with 6-month interval."

Trial Locations (1)

50200

Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai

All Listed Sponsors
collaborator

Faculty of Medicine, Chiang Mai University

UNKNOWN

lead

Chiang Mai University

OTHER

NCT06298708 - Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents | Biotech Hunter | Biotech Hunter